Suppliers / Vitalife Laboratories (A Div Arch Pharmalabs

Vitalife Laboratories (A Div Arch Pharmalabs

India Updated 9 July 2026

Vitalife Laboratories (A Div Arch Pharmalabs is an API manufacturer based in India. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 3 molecules. Its most recent recorded inspection, by US FDA, closed on 4 March 2019 as NAI.

2
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 4 March 2019 NAI US FDA
  • 1 April 2015 NAI US FDA
  • 12 April 2013 VAI US FDA
  • 20 November 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Mumbai, India Not on file
Gurugram, India 3005674618

What they file, and where

Molecule Regulators Docs
Clopidogrel US FDA 2
Caspofungin SFDA (Saudi Arabia) 1
Trandolapril EDQM 1

Also appears on these molecule pages

Clopidogrel API

Comparing suppliers?

Choose your molecules and target markets. Vitalife Laboratories (A Div Arch Pharmalabs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 4 March 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability